Produção Nacional
Revisado por pares
Cholesterol derivatives and breast cancer: oxysterols driving tumor growth and metastasis
2020; Future Medicine; Volume: 14; Issue: 14 Linguagem: Inglês
10.2217/bmm-2020-0460
ISSN1752-0371
AutoresMaria IBAC Sawada, Guilherme da Silva Ferreira, Marisa Passarelli,
Tópico(s)Estrogen and related hormone effects
ResumoBiomarkers in MedicineVol. 14, No. 14 EditorialCholesterol derivatives and breast cancer: oxysterols driving tumor growth and metastasisMaria IBAC Sawada, Guilherme da S Ferreira & Marisa PassarelliMaria IBAC Sawada https://orcid.org/0000-0002-2698-4496Serviço de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo 01246-903, BrazilCentro de Referência da Saúde da Mulher – Hospital Pérola Byington, São Paulo 01317-000, Brazil, Guilherme da S Ferreira https://orcid.org/0000-0001-7125-441XLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina da Universidade de São Paulo, São Paulo 01525-000, Brazil & Marisa Passarelli *Author for correspondence: E-mail Address: m.passarelli@uni9.pro.brhttps://orcid.org/0000-0002-9249-4698Serviço de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo 01246-903, BrazilLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina da Universidade de São Paulo, São Paulo 01525-000, BrazilPublished Online:24 Sep 2020https://doi.org/10.2217/bmm-2020-0460AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: breast cancercholesterolmetastasisoxysterolReferences1. Fitzmaurice C, Akinyemiju TF, Al Lami FH et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. JAMA Oncol. 4, 1553–1568 (2018).Crossref, Medline, Google Scholar2. Cedó L, Reddy ST, Mato E, Blanco-Vaca F, Escolà-Gil JC. HDL and LDL: potential new players in breast cancer development. J. Clin. Med. 8, 853 (2019).Crossref, CAS, Google Scholar3. Agnoli C, Berrino F, Abagnato CA et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case–control study. Nutr. Metab. Cardiovasc. Dis. 20, 41–48 (2010).Crossref, Medline, CAS, Google Scholar4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).Crossref, Medline, Google Scholar5. Griffiths WJ, Wang Y. Oxysterols as lipid mediators: their biosynthetic genes, enzymes and metabolites. Prostaglandins Other Lipid Mediat. 147, 106381 (2020).Crossref, Medline, CAS, Google Scholar6. Kloudova A, Guengerich FP, Soucek P. The role of oxysterols in human cancer. Trends Endocrinol. Metab. 28, 485–496 (2017).Crossref, Medline, CAS, Google Scholar7. Korytowski W, Wawak K, Pabisz P et al. Impairment of macrophage cholesterol efflux by cholesterol hydroperoxide trafficking. Arterioscler. Thromb. Vasc. Biol. 35, 2104–2113 (2015).Crossref, Medline, CAS, Google Scholar8. Gesquière L, Loreau N, Blache D. Impaired cellular cholesterol efflux by oxysterol-enriched high density lipoproteins. Free Radic. Biol. Med. 23, 541–547 (1997).Crossref, Medline, CAS, Google Scholar9. Nunes VS, Panzoldo NB, Leança CC et al. Increased 27-hydroxycholesterol plasma level in men with low high density lipoprotein-cholesterol may circumvent their reduced cell cholesterol efflux rate. Clin. Chim. Acta 433, 169–173 (2014).Crossref, Medline, CAS, Google Scholar10. Umetani M, Shaul PW. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol. Metab. 22, 130–135 (2011).Crossref, Medline, CAS, Google Scholar11. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625–4629 (1996).Medline, CAS, Google Scholar12. Nelson ER, Wardell SE, Jasper JS et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342, 1094–1098 (2013).Crossref, Medline, CAS, Google Scholar13. Torres CG, Ramí Rez ME, Cruz P, Epuñan MJ, Valladares LE, Sierralta WD. 27-Hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype. Oncol. Rep. 26, 389–397 (2011).Medline, CAS, Google Scholar14. Raza S, Ohm JE, Dhasarathy A et al. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells. Mol. Cell. Biochem. 410, 187–195 (2015).Crossref, Medline, CAS, Google Scholar15. Wu Q, Ishikawa T, Sirianni R et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 5, 637–645 (2013).Crossref, Medline, CAS, Google Scholar16. Zhu D, Shen Z, Liu J et al. The ROS-mediated activation of STAT-3/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells. Toxicol. Lett. 264, 79–86 (2016).Crossref, Medline, CAS, Google Scholar17. Umetani M, Domoto H, Gormley AK et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13, 1185–1192 (2007).Crossref, Medline, CAS, Google Scholar18. Mast N, Lin JB, Pikuleva IA. Marketed drugs can inhibit cytochrome P450 27A1, a potential new target for breast cancer adjuvant therapy. Mol. Pharmacol. 88, 428–436 (2015).Crossref, Medline, CAS, Google Scholar19. Kimbung S, Chang C, Bendahl P et al. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. Endocr. Relat. Cancer 24(7), 339–349 (2017).Crossref, Medline, CAS, Google Scholar20. Lu D-L, Le Cornet C, Sookthai D, Johnson TS, Kaaks R, Fortner RT. Circulating 27-hydroxycholesterol and breast cancer risk: results from the EPIC-Heidelberg cohort. J. Natl Cancer Inst. 111, 365–371 (2019).Crossref, Medline, Google Scholar21. Le Cornet C, Walter B, Sookthai D et al. Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort. Breast Cancer Res. 22, 23 (2020).Crossref, Medline, Google Scholar22. Dalenc F, Iuliano L, Filleron T et al. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: results of the OXYTAM study. J. Steroid Biochem. Mol. Biol. 169, 210–218 (2017).Crossref, Medline, CAS, Google Scholar23. Lappano R, Recchia AG, De Francesco EM et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 6, e16631 (2011).Crossref, Medline, CAS, Google Scholar24. Simigdala N, Gao Q, Pancholi S et al. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 18, 58 (2016).Crossref, Medline, Google Scholar25. Wang C-W, Huang C-C, Chou P-H et al. 7-ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway. Oncotarget 8, 66033–66050 (2017).Crossref, Medline, Google Scholar26. Kloudova-Spalenkova A, Ueng Y-F, Wei S, Kopeckova K, Peter Guengerich F, Soucek P. Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data. J. Steroid Biochem. Mol. Biol. 197, 105566 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByCholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression26 May 2022 | Frontiers in Oncology, Vol. 12Uncurtaining the pivotal role of ABC transporters in diabetes mellitus3 June 2021 | Environmental Science and Pollution Research, Vol. 28, No. 31Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases6 February 2021 | International Journal of Molecular Sciences, Vol. 22, No. 4 Vol. 14, No. 14 Follow us on social media for the latest updates Metrics Downloaded 92 times History Received 24 July 2020 Accepted 31 July 2020 Published online 24 September 2020 Published in print October 2020 Information© 2020 Future Medicine LtdKeywordsbreast cancercholesterolmetastasisoxysterolFinancial & competing interests disclosureThe authors would like to thank the financial support from Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP (grants #2019/18431-4 and 2016/15603-0 to MP) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – finance code 001, grant to GSF. MP is recipient of a research award from Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, Brazil. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)